Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery

Abstract

The main purpose of the present work was studying the biodistribution of amikacin solid lipid nanoparticles (SLNs) after pulmonary delivery to increase its concentration in the lungs for treatment of cystic fibrosis lung infections and also providing a new method for clinical application of amikacin. To achieve this aim, 99mTc labelled amikacin was loaded in cholesterol SLNs and after in vitro optimization, the desired SLNs and free drug were administered through pulmonary and i.v. routes to male rats and qualitative and biodistribution studies were done. Results showed that pulmonary delivery of SLNs of amikacin by microsprayer caused higher drug concentration in lungs than kidneys while i.v. administration of free drug caused reverse conditions. It seems that pulmonary delivery of SLNs may improve patients' compliance due to reduction of drug side effects in kidneys and elongation of drug dosing intervals due to the sustained drug release from SLNs.

Kanamycin Sulphate Loaded PLGA-Vitamin-E-TPGS Long Circulating Nanoparticles Using Combined Coating of PEG and Water-Soluble Chitosan

“…Intravenous administration of liposomes and solid lipid NPs to mice caused slower renal clearance, increased half-life, and increased AUC in lung [22]. …”

Nanoparticles: A Promising Drug Delivery Approach

“…Poly DL-lactide-co-glycolide nanoparticles of three frontline antitubercular drugs form a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis [79]. It was studied that pulmonary delivery of solid lipid nanoparticles of amikacin by microsprayer reduced its side effects in the kidneys and prolonged the dosing intervals due to the sustained drug release [80]. Gelatin and poly (lactic-co-glycolic) acid nanoparticles of plasmid DNA encoding a yellow fluorescent protein or rhodamine-conjugated erythropoietin for inhalational delivery enhances the duration of protein expression [81].…”

Consequences of cystic fibrosis transmembrane regulator mutations on inflammatory cells

“…In this sense, novel strategies are focus on the antibiotic encapsulation in nano-and microcarriers to improve the antibiotic biodisponibility, and to provide a proper molecular control release profile under the therapeutic window, avoiding the use of high concentrations which results in undesirable hepatic-and nephro-toxicity side effects. Among them, quinolones and amikacin have been encapsulated in liposomal formulation or solid lipid nanoparticles for pulmonary delivery, improving the biodistribution of the antibiotics and the patients' compliance [98]. Figure 4 shows images of amikacin loaded nanoparticles biodistribution in rats.…”